Cost-Benefit Analysis

"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.

Descriptor ID	D003362
MeSH Number(s)	N03.219.151.125
Concept/Terms	Cost-Benefit Analysis Cost-Benefit Analysis Analyses, Cost-Benefit Analysis, Cost-Benefit Cost-Benefit Analyses Cost Benefit Analysis Analyses, Cost Benefit Analysis, Cost Benefit Cost Benefit Analyses Cost Effectiveness Cost Effectiveness Effectiveness, Cost Cost-Benefit Data Cost-Benefit Data Cost Benefit Data Data, Cost-Benefit Cost-Utility Analysis Cost-Utility Analysis Analyses, Cost-Utility Analysis, Cost-Utility Cost Utility Analysis Cost-Utility Analyses Economic Evaluation Economic Evaluation Economic Evaluations Evaluation, Economic Evaluations, Economic Marginal Analysis Marginal Analysis Analyses, Marginal Analysis, Marginal Marginal Analyses Cost Benefit Cost Benefit Costs and Benefits Benefits and Costs Cost-Effectiveness Analysis Cost-Effectiveness Analysis Analysis, Cost-Effectiveness Cost Effectiveness Analysis

Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".

Health Care [N]
Health Care Economics and Organizations [N03]
Economics [N03.219]
Costs and Cost Analysis [N03.219.151]
Cost-Benefit Analysis [N03.219.151.125]

Below are MeSH descriptors whose meaning is related to "Cost-Benefit Analysis".

Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.

Bar chart showing 264 publications over 29 distinct years, with a maximum of 28 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	0	1	1
1998	0	3	3
2000	0	4	4
2001	0	3	3
2002	0	5	5
2003	0	8	8
2004	1	4	5
2005	1	7	8
2006	2	5	7
2007	0	5	5
2008	1	6	7
2009	0	10	10
2010	0	9	9
2011	0	9	9
2012	0	13	13
2013	0	7	7
2014	5	23	28
2015	3	13	16
2016	6	14	20
2017	5	13	18
2018	0	8	8
2019	2	9	11
2020	1	17	18
2021	2	8	10
2022	0	8	8
2023	1	5	6
2024	3	3	6
2025	0	3	3
2026	1	7	8

Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.

Joshi M, Kim K, Pickard AS, Sharp LK, Gerber BS, Touchette DR. Long-term cost-effectiveness of a mobile health intervention delivered by clinical pharmacists and community health workers for type 2 diabetes management in urban African American and Latinx populations. Am J Health Syst Pharm. 2026 Apr 07; 83(8):423-435.

View in: PubMed
Toan ATN, Phung TL, Tran-Duy A, Minh HV. Cost-Effectiveness of Add-On Ivabradine Versus Standard Pharmacotherapy in the Treatment of Heart Failure in Vietnam: An Analysis From a Health System Perspective. Value Health Reg Issues. 2026 Sep; 55:101594.

View in: PubMed
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.

View in: PubMed
Montano-Campos JF, Adair JE, Basu A, Kyeyune RB, Bayigga L, Kityo-Mutuluuza C, Hansen R. Cost-effectiveness of gene therapy for sickle cell disease in Uganda: tailoring high-income evidence to Uganda's context. Gene Ther. 2026 Mar; 33(2):109-117.

View in: PubMed
G?n?reux P, Reynolds MR, Kelley MA, Thompson C, Baron SJ. Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States. Value Health. 2026 Jul; 29(7):1171-1179.

View in: PubMed
Gottimukkala KSV, Lane DD, Cunningham R, Malik HS, Jwa Y, Cassidy ME, Castelli JMP, Enstrom MR, Poljakov K, Gastelum G, Ho SH, Tassa C, Adair JE. CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCs. Gene Ther. 2026 03; 33(2):188-202.

View in: PubMed
Driver L, Walsh CD, Schissel C, Meguerdichian DA, Duggan NM, Baugh CW, Goldsmith AJ. Utilizing an ultrasound-guided nerve block for management of sciatica in the ED: A national simulation-based cost savings analysis. Am J Emerg Med. 2026 Mar; 101:135-140.

View in: PubMed
Juvekar P, Whitmore R. Cost Effectiveness in the Treatment of Lumbar Spondylolisthesis. Neurosurg Clin N Am. 2026 Jan; 37(1):93-102.

View in: PubMed
Choi SE, Simon L. Projected Outcomes of Removing Fluoride From US Public Water Systems. JAMA Health Forum. 2025 05 02; 6(5):e251166.

View in: PubMed
Socolovsky C, Louisias M, Alsulami S, Petty CR, Trivedi M, Lai PS, Cunningham A, Gaffin J, Thorne P, Coull B, Koutrakis P, Baccarelli A, Gold DR, Adamkiewicz G, Permaul P, Banzon T, Hauptman M, Bartnikas LM, Baxi S, Sheehan WJ, Phipatanakul W, Samnaliev M. Cost-effectiveness of school integrated pest management and air filtration in students with asthma. Allergy Asthma Proc. 2025 05 01; 46(3):257-266.

View in: PubMed

People

Explore

Similar Concepts

Top Journals